The bill proposes fining branded drugmakers for not complying.
The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.
Bloomberg reports that India's Wockhardt has become an M&A target.
The generic ED pills sell for five cents less than Pfizer's branded blue pill, but the undercutting is a bit deeper.
Generics made up almost 75% of prescriptions in the United Kingdom last year.
The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.
Researchers at the Brigham and Women's Hospital found that continuity in color and shape have a significant impact on whether patients stick with a prescription regimen.
Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.
Prices for some generics are rising, thanks to limited competition.
Servier and Teva have been fined for keeping a generic heart medication off the market.
It's the generics maker's second recall of 2014.
The Indian Pharmaceutical Alliance makes a bid for legislators' attention.
Novartis no longer has a lock on the Diovan market: the FDA approved Ranbaxy's generic, which will be made in the US.
The FDA's seven-page letter outlines some of the problems the regulator has with one specific Sun site.
A three-year, $1 million project seeks an equation for generics and biosimilars.
Teva lost its most recent fight to keep generics of Copaxone off the market.
The Supreme Court denied Teva's request to keep branded Copaxone off the market while the appeals process shakes out.
Pfizer and Teva's settlement puts generic Celebrex on the market by December.
Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.
The announcement will create the fifth largest generics drug maker, reports Reuters.
At a hearing today, Public Citizen and the generics industry are sounding off on an FDA proposal that would allow generics firms to update labels, regardless of whether the brand has or hasn't.
The regulator disputes findings that generic heart drugs made abroad were contaminated.
GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.
The drugmaker's CEO tells Reuters it is in a good position to weather troubles in India's generics industry.
The drugmaker's outreach efforts involve switching patients to the latest—and patented—Copaxone formulation.
The White House's proposed FY 2015 budget gives an additional 1% to the FDA.
The regulator is allowing generic makers room on the OTC contraceptive shelf.
Critics say the FDA is not doing enough to ensure generics quality and that communications between industry and the regulator need to improve.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.